We updated the design of this site on September 25th. Learn more.

Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT00544362

First Posted: October 16, 2007

Last Update Posted: May 30, 2016

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Information provided by (Responsible Party):

Federation Francophone de Cancerologie Digestive

Purpose

RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving fluorouracil and cisplatin together with cetuximab and radiation therapy may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of fluorouracil and cisplatin when given together with cetuximab and radiation therapy in treating patients with esophageal cancer that can be removed by surgery.

Condition	Intervention	Phase
Esophageal Cancer	Biological: cetuximab Drug: cisplatin Drug: fluorouracil Procedure: conventional surgery	Phase 1 Phase 2


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment
Official Title:	Neoadjuvant Treatment for Operable Esophageal Cancer With 5-fluorouracil, Cisplatin, and Cetuximab and Concurrent Radiotherapy: Phase I/II Study

Resource links provided by NLM:

MedlinePlus related topics: Esophageal Cancer

Drug Information available for: Fluorouracil Cisplatin Cetuximab

Genetic and Rare Diseases Information Center resources: Esophageal Cancer

U.S. FDA Resources

Further study details as provided by Federation Francophone de Cancerologie Digestive:

Primary Outcome Measures:

Complete histologic response [ Time Frame: After Surgery ]
Tolerance to neoadjuvant therapy [ Time Frame: From Inclusion ]

Secondary Outcome Measures:

Progression-free and overall survival [ Time Frame: From inclusion ]
Mortality [ Time Frame: From Inclusion ]


Enrollment:	33
Study Start Date:	July 2007
Study Completion Date:	March 2013
Primary Completion Date:	January 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Neoadjuvant chemoradiotherapy Weekly cetuximab (400 mg/m2 one week before start of radiotherapy RT and 250 mg/m2 during radiotherapyRT), and 5 FU (500 mg/m2 per day D1-D4) combined with cisplatin CDDP (40 mg/m2 D1) on week 1 and 5	Biological: cetuximab Drug: cisplatin Drug: fluorouracil Procedure: conventional surgery

Detailed Description:

OBJECTIVES:

Primary

To determine the maximum tolerated dose of fluorouracil and cisplatin when administered with cetuximab concurrently with esophageal radiotherapy. (Phase I)
To determine the complete histological response rate (after surgical resection). (Phase II)

Secondary

To determine progression-free survival and overall survival. (Phase II)
To determine the rate of resection with negative margins (R0). (Phase II)
To determine the overall tolerance to neoadjuvant therapy. (Phase II)
To determine the postoperative morbidity and mortality. (Phase II)

OUTLINE: This is a multicenter study. This is a dose-escalation study of cisplatin and fluorouracil.

Patients receive cetuximab IV over 2 hours on day -7, then IV over 1 hour on days 1, 8, 15, 22, and 29. Patients also receive cisplatin IV over 1 hour on day 1 or 2 and fluorouracil IV continuously on days 1-4, 8-11, 15-18, 22-25, and 29-32. Patients undergo radiotherapy 5 days a week for 5 weeks, beginning on day 1 of chemotherapy. Treatment continues in the absence of disease progression or unacceptable toxicity.

Patients undergo surgery within 6-8 weeks after completion of chemoradiotherapy.

After completion of study therapy, patients are followed at 1 month, every 4 months for 2 years, and then every 6 months for 2 years.

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years to 75 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Inclusion criteria:

Histologically confirmed epidermoid or glandular carcinoma of the thoracic esophagus
- Invasive disease
- Only Siewert type I gastroesophageal carcinoma allowed
Resectable disease
- T1N+, T2N0, T2N+, T3N0, or T3N+ (stage II or III)
- No visceral metastases or mediastinal extensions compromising resectability

Exclusion criteria:

Inoperable disease
Invasion of the tracheo-bronchial tree
Recurring esophageal paralysis
Esopho-tracheal fistula
Cervical esophageal carcinoma (< 19 cm above the dental arches)
Multifocal esophageal carcinoma
Superficial esophageal carcinoma (T1N0)
Esophageal carcinoma in the lymph nodes that cannot be included in the radiotherapy field or cannot be completely surgically resected
Proven metastatic disease

PATIENT CHARACTERISTICS:

Inclusion criteria:

WHO performance status 0-1
Weight loss < 15%
Absolute neutrophil count ≥ 1,500/mm3
Platelet count ≥ 100,000/mm3
Creatinine ≤ 1.25 times upper limit of normal
PTT ≥ 80%
Albumin ≥ 35 g/L
FEV1 > 1 L
Not pregnant or nursing
Fertile patients of must use effective contraception

Exclusion criteria:

Known liver cirrhosis
Renal insufficiency
Respiratory insufficiency (i.e., severe dyspnea at rest or oxygen dependence)
Progressive coronary insufficiency
Myocardial infarction in the past 6 months
Legally incapacitated
Impossible to receive study therapy due to geographical, social, or psychological reasons
Noncompliant within constraints of the study
Hematologic malignancy or other cancer except carcinoma in situ of the uterine cervix, treated nonmelanoma skin cancer, or intramucous disease treated within the past 3 years

PRIOR CONCURRENT THERAPY:

Exclusion criteria:

Prior anticancer chemotherapy or radiotherapy
Treatment with endoprosthesis
Surgery (esophagectomy) planned without thoracotomy

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00544362

Locations


France
Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz
Besancon, France, 25030
Hopital Saint Andre
Bordeaux, France, 33075
C.H.U. de Brest
Brest, France, 29200
CHR Clermont Ferrand, Hotel Dieu
Clermont-Ferrand, France, 63058
Hopital Du Bocage
Dijon, France, 21034
Federation Francophone de Cancerologie Digestive
Dijon, France, 21079
Centre Oscar Lambret
Lille, France, 59020
Centre Hospital Universitaire Hop Huriez
Lille, France, 59037
CHU de la Timone
Marseille, France, 13385
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, France, 34298
Centre Hospitalier Lyon Sud
Pierre Benite, France, 69495
Centre Hospitalier Regional de Purpan
Toulouse, France, 31059
Centre Alexis Vautrin
Vandoeuvre-les-Nancy, France, 54511

Sponsors and Collaborators

Federation Francophone de Cancerologie Digestive

Investigators


Study Chair:	Martina Schneider	Federation Francophone de Cancerologie Digestive

More Information


Responsible Party:	Federation Francophone de Cancerologie Digestive
ClinicalTrials.gov Identifier:	NCT00544362 History of Changes
Other Study ID Numbers:	CDR0000564075 FFCD-0505 EU-20756 EUDRACT-2006-004770-27 MERCK-FFCD-0505
First Submitted:	October 13, 2007
First Posted:	October 16, 2007
Last Update Posted:	May 30, 2016
Last Verified:	May 2016

Keywords provided by Federation Francophone de Cancerologie Digestive:


adenocarcinoma of the esophagus squamous cell carcinoma of the esophagus stage IIIA esophageal cancer	stage IIIB esophageal cancer stage IIIC esophageal cancer stage IV esophageal cancer

Additional relevant MeSH terms:


Esophageal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Head and Neck Neoplasms Digestive System Diseases Esophageal Diseases Gastrointestinal Diseases Cisplatin	Cetuximab Fluorouracil Antineoplastic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs

To Top